[S17] Frontiers in Studies on Antiviral Infectious Diseases —Shaping Therapeutic Innovation through Target Molecules—

5:30 PM - 5:50 PM JST(8:30 AM - 8:50 AM UTC)

[S17-3] Study toward HIV latency-reversing agents based on the natural product 'ansellone A'

○Kenichi Murai¹ (1. School of Pharmaceutical Sciences, Wakayama Medical University)